

ASX ANNOUNCEMENT

14 December 2018

CORRECTION TO PREVIOUS 3B – STAFF PERFORMANCE RIGHTS

On 3 December 2018, Aspermont released an Appendix 3B - Staff Performance Rights, which stated the class of securities to be issued (section I) as 'Ordinary Shares'. The correct identification was 'Performance Rights'.

The remainder of the Appendix 3B was correct. Please find attached the corrected Appendix 3B.

For further information contact:

David Straface Company Secretary Tel: +61 8 6263 9100

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ASPERMONT LIMITED

ABN

66 000 375 048

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Performance Rights

2 Number of *securities issued or to be issued (if known) or maximum number which may be issued

2,500,000

⁺ See chapter 19 for defined terms.



3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the	Grant of Staff Performance Rights pursuant to the terms as approved by the Aspermont Board.
	amountoutstandingandduedatesforpayment;if	No payment is required upon the grant or vesting of Performance Rights.
	⁺ convertible securities, the conversion price and dates for conversion)	Each Staff Performance Right is the right to one fully paid Aspermont Limited Ordinary share, subject to the satisfaction of certain timing milestones:
		i. A 3 year period;
		ii. 33.3% of the total Performance Rights will vest per annum with the first tranche to be vested upon the issue of the Performance Rights, subject to exceptions which might give rise to earlier vesting as set out in the Performance Rights Plan.
		Any Performance Rights not vested on the measurement date will lapse.
4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional +securities do	
	not rank equally, please state:the date from which they do	
	• the extent to which they	
	participate for the next dividend, (in the case of a	
	trust, distribution) or interest payment	
	• the extent to which they do not rank equally, other than	
	in relation to the next	
	dividend, distribution or interest payment	
_	leave price or consideration	to = == 0.00
5	Issue price or consideration	\$25,750.00

+ See chapter 19 for defined terms.

ALUS D

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	1. Performance Incentive Rights
ба	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
бс	Number of <i>+</i> securities issued without security holder approval under rule 7.1	N/A
6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	N/A
бе	Number of <i>*</i> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of ⁺ securities issued under an exception in rule 7.2	2,500,000
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A

⁺ See chapter 19 for defined terms.



N/A

- 6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

67,558,489

30 November 2018

Number	+Class
2,095,833,244	Fully paid ordinary shares

⁺ See chapter 19 for defined terms.

9

	Number	+Class
Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	10,000,000	Options with strik \$0.01, expiry 31 Ju 2020
	10,000,000	Options with strik \$0.03, expiry 31 Ju 2020
	10,000,000	Options with strik \$0.03, expiry December 2022
	303,577,323	Options with strik \$0.03 expiry September 2025
	47,500,000	Performance Rights

10 Dividend policy (in the case of a Nil trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non- renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A

⁺ See chapter 19 for defined terms.



17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	N/A
	behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	N/A
	holders	
28	Date rights trading will begin (if	N/A
20	Date fights trading will begin (II	11/17

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

	applicable)	
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of *securities (*tick one*)

(a)

⁺Securities described in Part 1

(b)

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36

If the *securities are *equity securities, a distribution schedule of the additional

⁺ See chapter 19 for defined terms.



37

 T
 +61
 8
 6263
 9100
 E
 contact@aspermont.com

 A
 613-619
 Wellington
 St, Perth, Western Australia
 6000

 PO
 Box
 78, Leederville, Western Australia
 6902

 F
 +61
 8
 6263
 9148
 W www.aspermont.com
 ABN
 66
 000
 375
 048

*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38	Number of ⁺ securities for which ⁺ quotation is sought	N/A
39	⁺ Class of ⁺ securities for which quotation is sought	N/A
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities? If the additional ⁺ securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A
41	Reason for request for quotation now	N/A
	Example: In the case of restricted securities, end of restriction period (if issued upon conversion of	
	another ⁺ security, clearly identify that other ⁺ security)	

		Number	+Class
+securities	and ⁺ class of all quoted on ASX he ⁺ securities in clause		

⁺ See chapter 19 for defined terms.



 T
 +61 8 6263 9100
 E contact@aspermont.com

 A 613-619 Wellington St, Perth, Western Australia 6000
 PO Box 78, Leederville, Western Australia 6902

 F
 +61 8 6263 9148
 W www.aspermont.com
 ABN 66 000 375 048

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *+*securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those **securities* should not be granted **quotation*.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

.....Date: 14 December 2018 (Director/Company secretary)

Print name:

.DAVID STRAFACE

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

AUO DSD

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	1,856,225,458	
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 	26,729,640 7,861,545 Nil	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil	
"A"	1,890,816,643	

⁺ See chapter 19 for defined terms.



"B"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	283,622,496
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	216,064,007
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	216,064,007
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	283,622,496
Note: number must be same as shown in Step 2	
Subtract "C"	216,064,007
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	67,558,489
	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
" A " Note: number must be same as shown in	N/A	
Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of 		
securities on different dates as separate line items		

⁺ See chapter 19 for defined terms.



Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	N/A
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.